Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Fivetran, the global leader in data movement, today announced the opening of its new India headquarters in Bangalore's Ecoworld Tech Park. This strategic expansion underscores Fivetran's rapid growth ...

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Methode Electronics, Inc.  breached their fiduciary duties to ...

RBC Capital Markets reiterated their positive stance on Alnylam Pharmaceuticals (NASDAQ:ALNY), maintaining an Outperform rating and a price target of $300.00. According to InvestingPro data, analyst ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Polaris is a contrarian investment opportunity with a high dividend yield, strong financial stability, and potential for ...

There’s this strategy in business called the decoy effect, where marketers price things differently to manipulate customers.

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor. This article originally appeared here and ...